To identify other potentially attractive health-care stocks, we began with those listed on the Nasdaq, as well as any included in the S&P Composite 1500 Index that weren't also listed on the Nasdaq. We then pared the list to companies with market capitalizations of over $100 million covered by at least three analysts with majority "buy" ratings.
Here are the 10 health-care stocks with the greatest 12-month upside implied by analysts' price targets:
Company Ticker Closing price - March 13 Consensus price target Implied 12-month upside potential
Cytori Therapeutics Inc. US:CYTX $1.20 $5.67 372%
NeoStem Inc. US:NBS $4.03 $17.00 322%
Synta Pharmaceuticals Corp. US:SNTA $2.32 $8.75 277%
Galena Biopharma Inc. US:GALE $1.42 $5.14 262%
Stemline Therapeutics Inc. US:STML $16.01 $51.00 219%
Bind Therapeutics Inc. US:BIND $5.11 $16.00 213%
Inovio Pharmaceuticals Inc. US:INO $7.04 $22.00 213%
Peregrine Pharmaceuticals Inc. US:PPHM $1.40 $4.17 198%
Alcobra Ltd. US:ADHD $6.40 $18.67 192%
CTI BioPharma Corp. US:CTIC $1.97 $5.70 189%
Sources: Nasdaq, FactSet
This list is meant to provide a starting point for your own research if you're looking for possible up-and-comers. You might want to ask your adviser or broker for industry-specific research reports, or other research on individual companies.
In case you're wondering why we haven't included P/E or PEG ratios in the list above, it is because all of those companies are expected to continue losing money this year and in 2016.
March 17, 2015 05:46 ET (09:46 GMT)
